Abstract: Among other things, the present disclosure provides designed oligonucleotides and compositions thereof. In some embodiments, oligonucleotides and compositions of the present disclosure can provide high levels of adenosine editing. In some embodiments, oligonucleotides and compositions of the present disclosure are useful for treating various conditions, disorders or diseases, e.g., alpha- 1 antitrypsin deficiency. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine editing.
| # | Name | Date |
|---|---|---|
| 1 | 202417032570-STATEMENT OF UNDERTAKING (FORM 3) [24-04-2024(online)].pdf | 2024-04-24 |
| 3 | 202417032570-Sequence Listing in PDF [24-04-2024(online)].pdf | 2024-04-24 |
| 4 | 202417032570-REQUEST FOR EXAMINATION (FORM-18) [24-04-2024(online)].pdf | 2024-04-24 |
| 5 | 202417032570-POWER OF AUTHORITY [24-04-2024(online)].pdf | 2024-04-24 |
| 6 | 202417032570-NOTIFICATION OF INT. APPLN. NO. & FILING DATE (PCT-RO-105-PCT Pamphlet) [24-04-2024(online)].pdf | 2024-04-24 |
| 7 | 202417032570-FORM 18 [24-04-2024(online)].pdf | 2024-04-24 |
| 8 | 202417032570-FORM 1 [24-04-2024(online)].pdf | 2024-04-24 |
| 9 | 202417032570-DRAWINGS [24-04-2024(online)].pdf | 2024-04-24 |
| 10 | 202417032570-DECLARATION OF INVENTORSHIP (FORM 5) [24-04-2024(online)].pdf | 2024-04-24 |
| 11 | 202417032570-COMPLETE SPECIFICATION [24-04-2024(online)].pdf | 2024-04-24 |
| 12 | 202417032570-Proof of Right [02-05-2024(online)].pdf | 2024-05-02 |
| 13 | 202417032570-FORM 3 [23-10-2024(online)].pdf | 2024-10-23 |